Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.80
Nov 18 • 3:59 PM ET Dollar change-0.14 Percentage change(-6.96%)
Aftermarket Close
1.84
Aftermarket • 7:35 PM ET Dollar change+0.04 Percentage change(1.94%)
Index
-
Market Cap
144.86M
Enterprise Value
-46.63M
Income
-171.53M
Sales
0.00M
Book/sh
3.66
Cash/sh
2.42
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
92
IPO
Feb 09, 2024
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.49
P/C
0.75
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
4.08
Current Ratio
4.08
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-1232.22
EPS next Y
-1.82
EPS next Q
-0.44
EPS this Y
46.55%
EPS next Y
20.93%
EPS next 5Y
27.18%
EPS past 3/5Y
-2681.49% -572.84%
Sales past 3/5Y
- -
EPS Y/Y TTM
-132725.78%
Sales Y/Y TTM
-
EPS Q/Q
58.59%
Sales Q/Q
-
Insider Own
43.59%
Insider Trans
-0.00%
Inst Own
57.51%
Inst Trans
6.73%
ROA
-41.28%
ROE
-46.35%
ROIC
-58.11%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-23.80%
SMA50
-44.86%
SMA200
-75.91%
Trades
Shs Outstand
80.23M
Shs Float
45.27M
52W High
14.87 -87.86%
52W Low
1.92 -5.99%
Volatility
15.53% 10.79%
ATR (14)
0.27
RSI (14)
27.69
Beta
1.07
Rel Volume
0.93
Avg Volume
619.43K
Volume
576,754
Perf Week
-29.49%
Perf Month
-33.64%
Perf Quarter
-80.12%
Perf Half Y
-79.51%
Perf YTD
-85.58%
Perf Year
-86.61%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
1.94
Price
1.80
Change %
-6.96%
Consensus
Strong Buy
Avg. Price Target
$16.78
Implied Upside
+829.6%
Analysts9incl. previous ratings
Rating Distribution9 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 08, 2026Initiated
JPM logoJJP Morgan
Overweight$27+1,395.8%
Jun 22, 2026Resumed
OPY logoOOppenheimer
Outperform$22+1,118.8%
May 11, 2026Initiated
CCanaccord Genuity
Buy$23+1,174.2%
Feb 11, 2026Initiated
SF logoSStifel
Buy$23+1,174.2%
Jan 09, 2026Initiated
RJF logoRRaymond James
Outperform$24+1,229.6%
Dec 05, 2025Initiated
MS logoMMorgan Stanley
Overweight$20+1,008.0%
Sep 17, 2025Initiated
LLeerink Partners
Outperform$25+1,285.0%
Sep 15, 2025Initiated
HH.C. Wainwright
Buy$27+1,395.8%
Aug 15, 2025Initiated
PPiper Sandler
Overweight$21+1,063.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PEDRO BELTRANDirectorNov 18 '26Proposed Sale1.941,8703,628Nov 18 04:35 PM
Cobo MarcPrincipal Accounting OfficerNov 13 '26Sale2.377818513,734Nov 17 04:35 PM
MARC COBOOfficerNov 13 '26Proposed Sale2.3578183Nov 13 04:24 PM
Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.
Executive ChairmanDr. Neil Kumar Ph.D.
Co-FounderDr. Frank P. McCormick Ph.D.
M.D.Dr. Yong Ben M.B.A.
Ph.D.Dr. Pedro J. Beltran M.D.
VP of Finance & ControllerMr. Marc Cobo